Identification

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates
Name
CT-011
Accession Number
DB05916
Type
Biotech
Groups
Investigational
Biologic Classification
Protein Based Therapies
Other protein based therapies
Description

CT-011 is a humanized monoclonal antibody directed against a B7 family-associated protein, in patients with advanced haematological malignancies. It is directed against human PD-1 (programmed cell death 1; PDCD1), with immunomodulating and antitumor activities.

Protein chemical formula
Not Available
Protein average weight
Not Available
Sequences
Not Available
Synonyms
Not Available
Categories
UNII
Not Available
CAS number
Not Available

Pharmacology

Indication

Investigated for use/treatment in cancer/tumors (unspecified).

Pharmacodynamics
Not Available
Mechanism of action

CT-011 blocks interaction between the receptor PD-1 with its ligands, PD-1 ligand 1 (PD-1L1) and PD-1 ligand 2 (PD-1L2), resulting in the attenuation of apoptotic processes in lymphocytes, primarily effector/memory T cells, and the augmentation of the anti-tumor activities of NK cells. PD-1 is an inhibitory receptor belonging to the B7-receptor family that is expressed on lymphocytes and myeloid cells; its ligands, PD-1L1 and PD-1L2, are expressed not only by hematopoietic cells but also by cells in non-lymphoid tissues.

TargetActionsOrganism
UProgrammed cell death protein 1Not AvailableHumans
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AbciximabThe risk or severity of adverse effects can be increased when Abciximab is combined with CT-011.
AbituzumabThe risk or severity of adverse effects can be increased when CT-011 is combined with Abituzumab.
AbrilumabThe risk or severity of adverse effects can be increased when CT-011 is combined with Abrilumab.
AdalimumabThe risk or severity of adverse effects can be increased when Adalimumab is combined with CT-011.
AdecatumumabThe risk or severity of adverse effects can be increased when Adecatumumab is combined with CT-011.
AducanumabThe risk or severity of adverse effects can be increased when CT-011 is combined with Aducanumab.
AfelimomabThe risk or severity of adverse effects can be increased when Afelimomab is combined with CT-011.
AlemtuzumabThe risk or severity of adverse effects can be increased when Alemtuzumab is combined with CT-011.
AlirocumabThe risk or severity of adverse effects can be increased when CT-011 is combined with Alirocumab.
AmatuximabThe risk or severity of adverse effects can be increased when CT-011 is combined with Amatuximab.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

References

General References
Not Available
External Links
PubChem Substance
347910312
Wikipedia
CT-011

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1WithdrawnTreatmentBreast Cancer / Malignant Neoplasm of Colon / Malignant Neoplasm of Pancreas / Ovarian Cancer / Sarcomas1
1, 2CompletedTreatmentMultiple Myeloma (MM)1
1, 2TerminatedTreatmentChronic Hepatitis C Virus (HCV) Infection1
1, 2TerminatedTreatmentPrimary Hepatocellular Carcinoma1
2Active Not RecruitingTreatmentMultiple Myeloma (MM)1
2CompletedTreatmentLymphoma, Large Cell, Diffuse / Lymphoma, Mixed Cell, Diffuse / Primary mediastinal large B-cell lymphomas1
2CompletedTreatmentMalignant Lymphomas1
2CompletedTreatmentMalignant Melanoma / Melanoma1
2CompletedTreatmentMetastatic Colorectal Cancer (MCRC)1
2TerminatedTreatmentCancer of the Pancreas / Malignant Neoplasm of Pancreas / Neoplasms Pancreatic / Neoplasms, Pancreatic1
2TerminatedTreatmentProstatic Neoplasms1
2TerminatedTreatmentRenal Cell Adenocarcinoma1
2TerminatedTreatmentStage III Diffuse Large B-Cell Lymphoma / Stage IV Diffuse Large B-Cell Lymphoma1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available

Taxonomy

Description
Not Available
Kingdom
Organic Compounds
Super Class
Organic Acids
Class
Carboxylic Acids and Derivatives
Sub Class
Amino Acids, Peptides, and Analogues
Direct Parent
Peptides
Alternative Parents
Not Available
Substituents
Not Available
Molecular Framework
Not Available
External Descriptors
Not Available

Targets

Kind
Protein
Organism
Humans
Pharmacological action
Unknown
General Function
Signal transducer activity
Specific Function
Inhibitory cell surface receptor involved in the regulation of T-cell function during immunity and tolerance. Upon ligand binding, inhibits T-cell effector functions in an antigen-specific manner. ...
Gene Name
PDCD1
Uniprot ID
Q15116
Uniprot Name
Programmed cell death protein 1
Molecular Weight
31646.635 Da

Drug created on November 18, 2007 11:28 / Updated on December 02, 2019 07:16